INBX
Inhibrx Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$109.35
+4.41%Sep 8, 2026, 11:30 UTC
Inhibrx announced that its experimental OX40-targeting immunotherapy showed responses in patients with head and neck cancer, particularly in a subset with HPV-positive tumors.
Jul 16, 2026, 13:00 UTC
Inhibrx entered into an amended loan agreement with Oxford Finance, expanding the total facility to $500.0 million and receiving an initial $100.0 million tranche.
Source:Jun 15, 2026, 13:15 UTC
Inhibrx announced that the U.S. FDA accepted for filing its Biologics License Application for ozekibart to treat unresectable or metastatic conventional chondrosarcoma.
Source: